150,000 Shares in CRISPR Therapeutics AG $CRSP Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 1st quarter, HoldingsChannel reports. The institutional investor acquired 150,000 shares of the company’s stock, valued at approximately $7,136,000.

A number of other large investors have also bought and sold shares of CRSP. Mcguire Capital Advisors Inc. purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at $25,000. Ramirez Asset Management Inc. purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $26,000. Rothschild Investment LLC lifted its stake in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after buying an additional 502 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its holdings in shares of CRISPR Therapeutics by 196.9% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after acquiring an additional 382 shares during the period. Finally, Oakworth Capital Inc. purchased a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $34,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the transaction, the insider owned 19,357 shares in the company, valued at approximately $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 5.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CRSP shares. Evercore reissued an “outperform” rating and set a $76.00 price objective on shares of CRISPR Therapeutics in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Wall Street Zen cut shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 5th. UBS Group set a $80.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 12th. Finally, Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the stock an “equal weight” rating in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.

CRISPR Therapeutics Stock Down 2.1%

Shares of NASDAQ:CRSP opened at $46.54 on Friday. The stock has a market capitalization of $4.49 billion, a P/E ratio of -7.48 and a beta of 1.71. The stock’s 50-day moving average price is $52.66 and its 200-day moving average price is $52.72. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics AG has a 12-month low of $44.12 and a 12-month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. The company had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -4.9 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.